Congress to Feature Trump on $100 Bill?
A shocking new plan was just introduced in Washington; to celebrate Trump's new "golden age" by placing him on the $100 bill. In the months ahead, this former Presidential Advisor predicts the government will release a massive multi-trillion-dollar asset which it has held back for more than a century.
Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Trump may become the face of economic discontent, a year after such worries helped him win big
WASHINGTON (AP) — President got a serious that he’s out of touch with their fears about a deteriorating U.S. economy.
The Market Just Crossed a Dangerous Line - Ad
The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous. He says it's about to change everything you know about money.
Trump administration moves to loosen restrictions it once supported on a harmful pollutant
WASHINGTON (AP) — Near the end of his first term, President Donald Trump signed into law a bill that and air conditioners. The bipartisan measure brought environmentalists and major business groups into rare alignment on the contentious issue of climate change and won praise across the political spectrum.
Why Is Scholar Rock Holding Stock Climbing Today?
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
LOCALIZE IT: At least 30 babies in 15 states sickened by growing infant botulism outbreak
EDITORS/NEWS DIRECTORS:
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Metals... Not Missles... Is the New Arms Race - Ad
China and Russia control 70% of the world's critical minerals, giving them leverage over the West. One N. American discovery could help shift that balance by developing the metals essential for defense systems.
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
NEW YORK (AP) — The MacArthur Foundation is awarding $100 million to a private pandemic prevention network across Africa, offering critical support to infectious disease surveillance at a time when governments are reducing global health spending.
This Is the Type of Drill Hole That Changes Everything - Ad
A 19.5 metre zone returned 6.93% CuEq with a core 6.3 metre interval at 17.91%. The structure is bigger, richer, and more gold-loaded than expected. Drilling is active, and majors are watching.
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
Novo chops Wegovy prices, but doctors still see affordability challenges for patients
Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.
Trump Signs Law to Launch Dollar 2.0 - Ad
Trump just signed law S.1582, unleashing the biggest money shift in 100+ years. For the first time since 1913, private firms - not the Fed - can mint a "Dollar 2.0." Treasury says it could drain $6.6T from banks and pay 10X current savings rates. Early investors in minting firms could see 40X returns by 2032.
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
Congress to Feature Trump on $100 Bill? - Ad
A shocking new plan was just introduced in Washington; to celebrate Trump's new "golden age" by placing him on the $100 bill. In the months ahead, this former Presidential Advisor predicts the government will release a massive multi-trillion-dollar asset which it has held back for more than a century.
Workers take on side jobs to combat stagnant salaries and insecurity about employment
NEW YORK (AP) — As workers face , inflation and , some have decided to branch out from their traditional careers. They're taking on side jobs to bring in additional income and provide a backup plan should they , or adding second, third and sometimes fourth jobs — what some call “polyworking” — to the mix.
Federal workers question whether the longest government shutdown was worth their sacrifice
WASHINGTON (AP) — Jessica Sweet spent cutting back. To make ends meet, the Social Security claims specialist drank only one coffee a day, skipped meals, cut down on groceries and deferred paying some household bills. She racked up spending on her credit card buying gas to get to work.
"Tech Prophet" Who Predicted the iPhone Now Predicts... - Ad
George Gilder - who predicted the iPhone 17 years early and gave Reagan the first microchip - is making his boldest call yet. He says an American nanotech "super-convergence" could mint more millionaires than any event in recent memory. He's found 3 stocks set to benefit the most.
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
More than 80 nonprofits receive $250M for global women's health from Melinda French Gates
More than 80 organizations that provide health care for women all over the world received grants Wednesday totaling after a year-long application process.
Gold Near $4,073. Copper Tight. This Drill Hit Came Just in Time. - Ad
Dual exposure to two surging metals, plus 17.91% CuEq over mineable width, and infrastructure on site - this is what juniors dream of. And the market is just starting to notice.
FDA names longtime cancer scientist Pazdur to lead drug center
WASHINGTON (AP) — The Food and Drug Administration on Tuesday named a longtime regulator of cancer medicines to lead the agency's drug center, replacing the who was recently ousted after an .
Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact
BofA expects Medtronic to post over 5% second-quarter revenue growth and maintain strong momentum through 2026, driven by robust procedure trends.
From Strong to Stunning: New Drill Hole Sets a New Bar - Ad
Earlier holes showed 2.4% and 2.7% CuEq. This new hit just delivered 6.93% over nearly 20 metres. That's a game-changer - and it comes with deep insider alignment and an active program.
A deal to end the government shutdown is on track but faces hurdles
WASHINGTON (AP) — A legislative package to end appears on track Monday after a handful of Senate Democrats joined with Republicans to break the impasse in what has become of federal , the longest in history.
America's Defense Future Starts Underground - Ad
A N. American metals project just caught the attention of Rio Tinto - a mining giant. With four projects in key regions, this firm is aligned with Washington's push to rebuild the defense-metal supply chain.
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.
PHOTO ESSAY: Coal miners with black lung fight Trump administration rollback of safety protections
OAK HILL, W.Va. (AP) — Deep in the hills of West Virginia, coal mining and the dangers that come with it have been a part of families’ lives for generations. Death and tragedy are woven into history, but there’s also a fierce legacy of miners fighting for — and winning — protections that have benefitted workers nationwide.
The Market Just Crossed a Dangerous Line - Ad
The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous. He says it's about to change everything you know about money.
Trump unveils deal to expand coverage and lower costs on obesity drugs
WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
Charles River Beat Expectations But Why Is The Stock Falling?
Charles River stock dips as Q3 revenue slips, EPS beats estimates, and company raises 2025 outlook with cost cuts and $1 billion buyback plan.
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.
Alvotech Shares Plunge 33% After FDA Flags Issues
Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 revenue and EBITDA outlook.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.